Literature DB >> 12801062

Autologous cancer vaccine: a novel formulation.

Tadao Ohno1.   

Abstract

A novel cancer vaccine consisting of fixed autologous cancer tissue-fragments, microparticles encapsulating cytokines, and an adjuvant was developed. In a Phase I/IIa clinical trial, vaccination to patients after resection of hepatocellular carcinoma induced significantly longer time before the first recurrence than that in historical control patients operated in the same department (P < 0.05). This formulation will be promising against recurrence of many types of human cancers.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12801062     DOI： 10.1111/j.1348-0421.2003.tb03393.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN： 0385-5600            Impact factor:   1.955


  4 in total

Review 1.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

Review 2.  Immunotherapeutic advancements for glioblastoma.

Authors:  Leonel Ampie; Eric C Woolf; Christopher Dardis
Journal:  Front Oncol       Date:  2015-01-29       Impact factor: 6.244

3.  Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report.

Authors:  Takayuki Morimoto; Ryosuke Matsuda; Tsutomu Nakazawa; Fumihiko Nishimura; Ichiro Nakagawa
Journal:  Brain Tumor Res Treat       Date:  2022-04

4.  Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine.

Authors:  Jui-Tung Chen; Tadao Ohno
Journal:  Clin Case Rep       Date:  2015-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.